- Home
- MNTK vs CAPR Comparison
MNTK vs CAPR Comparison
Compare MNTK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- CAPR
- Stock Information
- Founded
- MNTK 1980
- CAPR 2005
- Country
- MNTK United States
- CAPR United States
- Employees
- MNTK N/A
- CAPR N/A
- Industry
- MNTK Natural Gas Distribution
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNTK Utilities
- CAPR Health Care
- Exchange
- MNTK Nasdaq
- CAPR Nasdaq
- Market Cap
- MNTK 622.2M
- CAPR 600.7M
- IPO Year
- MNTK 2021
- CAPR N/A
- Fundamental
- Price
- MNTK $2.36
- CAPR $6.97
- Analyst Decision
- MNTK Hold
- CAPR Strong Buy
- Analyst Count
- MNTK 3
- CAPR 7
- Target Price
- MNTK $3.33
- CAPR $39.29
- AVG Volume (30 Days)
- MNTK 155.1K
- CAPR 2.0M
- Earning Date
- MNTK 05-08-2025
- CAPR 05-13-2025
- Dividend Yield
- MNTK N/A
- CAPR N/A
- EPS Growth
- MNTK N/A
- CAPR N/A
- EPS
- MNTK 0.07
- CAPR N/A
- Revenue
- MNTK $175,736,000.00
- CAPR $22,270,465.00
- Revenue This Year
- MNTK $4.25
- CAPR $78.85
- Revenue Next Year
- MNTK $23.36
- CAPR $157.99
- P/E Ratio
- MNTK $34.50
- CAPR N/A
- Revenue Growth
- MNTK 0.48
- CAPR N/A
- 52 Week Low
- MNTK $1.75
- CAPR $3.52
- 52 Week High
- MNTK $6.22
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- MNTK 49.44
- CAPR 29.15
- Support Level
- MNTK $2.09
- CAPR $12.16
- Resistance Level
- MNTK $2.27
- CAPR $13.22
- Average True Range (ATR)
- MNTK 0.14
- CAPR 1.24
- MACD
- MNTK 0.04
- CAPR -0.58
- Stochastic Oscillator
- MNTK 69.39
- CAPR 5.06
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.